Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing

Tuo Wei\(^1\), Qiang Cheng\(^1\), Yi-Li Min\(^2\), Eric N. Olson\(^2\), & Daniel J. Siegwart\(^1\)

CRISPR-Cas9 has emerged as a powerful technology that relies on Cas9/sgRNA ribonucleoprotein complexes (RNPs) to target and edit DNA. However, many therapeutic targets cannot currently be accessed due to the lack of carriers that can deliver RNPs systemically. Here, we report a generalizable methodology that allows engineering of modified lipid nanoparticles to efficiently deliver RNPs into cells and edit tissues including muscle, brain, liver, and lungs. Intravenous injection facilitated tissue-specific, multiplexed editing of six genes in mouse lungs. High carrier potency was leveraged to create organ-specific cancer models in livers and lungs of mice though facile knockout of multiple genes. The developed carriers were also able to deliver RNPs to restore dystrophin expression in DMD mice and significantly decrease serum PCSK9 level in C57BL/6 mice. Application of this generalizable strategy will facilitate broad nanoparticle development for a variety of disease targets amenable to protein delivery and precise gene correction approaches.

\(^1\)Department of Biochemistry, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
\(^2\)Department of Molecular Biology, Hamon Center for Regenerative Science and Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
\(^3\)Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
\(^4\)These authors contributed equally: Tuo Wei, Qiang Cheng. *Email: Daniel.Siegwart@UTSouthwestern.edu*
The clustered regularly interspaced short-palindromic repeat (CRISPR)-associated protein 9 (CRISPR-Cas9) nuclelease system has emerged as a powerful genome editing tool for various biomedical applications\(^1\). The single-guide RNA (sgRNA) recognizes specific target genomic loci and guides the Cas9 nuclease to cleave the recognized DNA sequence. Induced double-stranded breaks are repaired through non-homologous end joining to generate insertions or deletions (termed Indels) or homology-directed repair for gene modifications. Among various strategies\(^1\), delivery of Cas9/sgRNA RNPs is an attractive approach because it is the most direct and rapid method for CRISPR-Cas gene editing and has been shown to have less off-target effects and lower immunogenicity\(^1\).

Despite this obvious promise, delivery of RNPs is the most challenging approach for non-viral carriers due to the large size of Cas9, the highly negative charge of sgRNAs, and the difficulty of protecting RNPs from degradation or denaturation during the entire formulation and delivery process. To date, several non-viral nanovehicles have been reported for in vitro RNP delivery into cells, including DNA nanocages,\(^2\) cationic lipid nanoparticles, and lipopolymers,\(^3\) gold-based nanoparticles,\(^4\) and zeolitic imidazole frameworks.\(^5\) Most approaches utilize host–guest and electrostatic interactions, often adsorbing RNPs after nanoparticle formation. Consequently, it is difficult to control the size, uniformity, and stability of the resulting formulations, which has limited in vivo applications to local administrations, such as inner ears, muscles, brain, and tumors.\(^6\) At present, development of stable nanoparticles for systemic delivery of RNPs to targeted organs remains elusive.

Based on a fundamental understanding of these issues, we developed a generalizable engineering approach that is rationally designed to preserve RNP integrity through inclusion of a permanently cationic lipid in established ionizable lipid nanoparticles (LNPs) formulations (Fig. 1a). We show that the supplemental lipid component mediates encapsulation of RNPs with retention of activity and redirects DNA editing to targeted tissues, including the lungs and liver following low-dose intravenous (IV) injection. We further demonstrate that this approach is applicable to three different classes of LNPs, including dendrimer lipid nanoparticles (DLNPs), stable nucleic acid lipid particles (SNALPs), and lipid-like nanoparticles (LLNPs). This led to development of modified lipid nanoparticles capable of rapidly editing the DNA of cells in different tissues. High DLNP potency allowed facile creation of organ-specific cancer models in the livers and lungs of mice. Modified DLNPs also delivered RNPs to restore dystrophin expression in DMD mice and significantly decrease serum PCSK9 level in C57BL/6 mice. Collectively, these results indicate that the generalizable approach developed here is applicable to diverse gene editing areas, including fundamental biology modeling and therapeutic intervention.

**Results**

**Development of a methodical strategy to deliver RNPs.** Central to our development of a generalizable strategy to load and stabilize RNPs into nanoparticles was the realization that established dilution methods (e.g., ethanol/acidic buffer) commonly used to formulate various lipid- and polymer-based nanoparticles are discordant with delivery of RNPs. We observed that Cas9 RNPs denature in acidic buffer, resulting in an increase of hydrodynamic size from 10 to 150 nm (Fig. 1b). This makes RNP encapsulation into monodisperse nanoparticles difficult if not impossible. We focus here on lipid nanoparticles (LNPs) because they are the most efficacious class of RNA delivery carriers\(^1\) in preclinical models and in humans.\(^3\) Among the four components of LNPs (ionic cationic lipids, zwiterionic phospholipids, cholesterol, and poly(ethylene glycol) (PEG) lipids), ionizable cationic lipids with pH 4 around 6.4 are essential for activity because they bind negatively charged RNAs at the pH of mixing (e.g., pH 4 when the amines are protonated), lose charge at neutral pH before cellular uptake, and then acquire charge again as the pH in endosomes decreases to fuse with endosomal membranes and enable release of cargos to the cytoplasm. However, this critical feature prevents effective encapsulation of cargos at neutral pH because ionizable cationic lipids are uncharged at neutral pH. To overcome this challenge, we hypothesized that supplemental addition of a cationic lipid that would be positively charged at neutral pH would allow for encapsulation of RNAs and proteins using neutral buffers (instead of acidic buffers), thus preserving the essential tertiary structure and stability of RNP s (Fig. 1a).

To evaluate this strategy, we selected 5A2-S8 as the ionizable cationic lipid because 5A2-S8 LNPs safely delivered short small-interfering RNAs (siRNAs)/microRNAs (miRNAs) and long mRNAs to mice with compromised liver function, including MYC-driven liver cancer\(^6\) or genetic knockout of fumarylacetoacetase hydrolase (FAH).\(^7\) Excitingly, introduction of a permanently cationic lipid (e.g., 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)) into traditional 4-component 5A2-S8 LNP formulations indeed allowed controlled self-assembly to occur by mixing an ethanol solution of lipids with a phosphate-buffered saline (PBS) solution of RNPs (1/3, v/v). We evaluated incorporation of DOTAP from 5 to 60 mole% of total lipids (Supplementary Figs. 1 and 20), which revealed higher levels of gene editing at 10–20% in vitro and formation of stable RNP-loaded nanoparticles with size <200 nm (Supplementary Fig. 2).

Initially using sgRNA targeting reporter Luciferase (sgLuc), we observed that the size of LNPs with 10 mole% DOTAP incorporation termed 5A2-DOT-10 (5A2-S8/DOTAP) into traditional 4-component 5A2-S8 LNPs formulations indeed allowed controlled self-assembly to occur by mixing an ethanol solution of lipids with a phosphate-buffered saline (PBS) solution of RNPs (1/3, v/v). We evaluated incorporation of DOTAP from 5 to 60 mole% of total lipids (Supplementary Figs. 1 and 20), which revealed higher levels of gene editing at 10–20% in vitro and formation of stable RNP-loaded nanoparticles with size <200 nm (Supplementary Fig. 2). We hypothesized that supplemental addition of a cationic lipid that would be positively charged at neutral pH would allow for encapsulation of RNAs and proteins using neutral buffers (instead of acidic buffers), thus preserving the essential tertiary structure and stability of RNP s (Fig. 1a).

**Highly efficient genome editing was achieved in vitro.** To quantify gene editing efficacy, we employed HeLa-Luc and HeLa-GFP reporter cells. Examining different Cas9/sgLuc ratios, gene editing was higher at 1/3 and 1/5 than at 1/1 (Fig. 2a). The result of a T7 Endonuclease I (T7EI) assay demonstrated that most all
target DNA bands (720 bp) were cut into two cleavage bands (536 bp and 184 bp) at ratios of 1/3 and 1/5. No cleavage bands were observed with control treatment groups. Therefore, we fixed the molar ratio of Cas9/sgRNA at 1/3 for all subsequent studies. To test our hypothesis that neutral pH buffer is required to encapsulate RNPs with preservation of Cas9 function, we also evaluated the gene editing efficiency of 5A2-DOT-10 prepared using pH 4 citrate buffer. No cleavage bands were observed (Fig. 2a) by T7EI. This result was further confirmed by Sanger sequencing, providing additional evidence that the conventional acid-based formulation methods could not produce efficacious NPs. Switching to GFP-expressing cells, 5A2-DOT-10...
Fig. 1 A modular approach was developed to enable systemic nanoparticle delivery of CRISPR-Cas9 RNPs for tissue-specific genome editing. a Addition of a permanently cationic supplemental component (e.g., DOTAP) into traditional LNP formulations enabled encapsulation and protection of Cas9/sgRNA complexes using neutral buffers during nanoparticle formation. Precise tuning of the DOTAP percentage mediated tissue-specific gene editing. b Size distribution of Cas9/sgLuc RNPs prepared in PBS buffer (pH 7.4) and citrate buffer (pH 4.0). The size increase is likely due to denaturization. c Size distribution of 5A2-DOT-10 encapsulating Cas9/sgLuc RNPs prepared in PBS and citrate buffer. 5A2-DOT-10 prepared without RNPs was used as control. d Size distribution of Cas9/sgRNA RNPs with Cas9/sgLuc molar ratio of 1/1, 1/3, and 1/5. e Zeta potential of Cas9/sgRNA RNPs showing decreasing charge. Data are presented as mean ± s.e.m. (n = 3 biologically independent samples). g No significant difference of zeta potential was observed for 5A2-DOT-10 encapsulating Cas9/sgLuc with different molar ratios. Data are presented as mean ± s.e.m. (n = 3 biologically independent samples). h Time-dependent cellular uptake of 5A2-DOT-10 LNPs encapsulating EGFP-fused Cas9/sgRNAs showing cytoplasmic release and gradual entry into the nucleus (n = 3 biologically independent samples). Scale bar: 10 μm. Red arrows show distribution of EGFP-fused Cas9/sgRNAs inside cells.

Source data are in the Source Data file.
neutral buffers, we formulated LNPs in PBS, Opti-MEM media, stability. To test if our methodology is compatible with other standard acidic buffer with PBS buffer to maintain protein directions for clinically translatable treatment of human diseases. cationic lipids that are positively charged at pH 7.4. As our lipid nanoparticles (DLNPs, LLNPs, SNALPs) and for other with different chemical structures (Supplementary Fig. 6h). These modiﬁed nanoparticles could efﬁciently edit cells whereas pre-oxidized gene editing packages were stored at 4 °C for 2 months. The nanoparticle diameter and PDI was monitored over time (mean ± s.e.m., n = 4 biologically independent samples). Periodic treatment of HeLa-GFP cells with stored LNPs showed that no activity was lost, indicating long-term LNP and RNP stability (mean ± s.e.m., n = 3 biologically independent samples). Mean ﬂuorescence intensity (%) of HeLa-GFP cells after treatment with Cas9/sgGFP alone, 5A2-DOT-10, C12-200-DOT-10, MC3-DOT-10, C12-200 LNPs, MC3 LNPs, and Cas9/sgGFP-loaded RNAiMAX (mean ± s.e.m., n = 3 biologically independent samples). The GFP ﬂuorescence signiﬁcantly decreased after treated with all three DOTAP-modiﬁed formulations. TIDE analysis of Sanger sequencing data further conﬁrmed the highest gene editing efﬁciency was with 5A2-DOT-10 LNPs. Mean ﬂuorescence intensity (%) of Hela-GFP cells after treatment with 5A2-DOT-10 formulated with Cas9/sgGFP in different buffers. Neutral buffer was required for RNP encapsulation and delivery (mean ± s.e.m., n = 3 biologically independent samples). One-way ANOVA followed by Dunnett’s multiple comparison test was used to determine the signiﬁcance in g and h. (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). Source data are in the Source Data file.

The approach is applicable to other LNP types and neutral buffers. The strategy of adding a permanently cationic lipid into classical 4-component LNPs to achieve efﬁcient RNP delivery was not limited to the dendrimer-based ionizable lipid, 5A2-S8. To prove this, we included supplemental DOTAP into nanoformulations prepared using other classes of ionizable materials: the well-known 4-4-4 MC3-DMA lipid used in FDA-approved Onpattro® and the C12-200 lipidoid (Supplementary Fig. 6a, b). Even though they have very different chemical structures compared to 5A2-S8 (Supplementary Fig. 6c), all DOTAP-modiﬁed nanoparticles could efﬁciently edit cells whereas previously established C12-200 or MC3 formulations without DOTAP showed low editing efﬁciency (Fig. 2g and Supplementary Fig. 6d). 5A2-DOT-10 also achieved higher editing efﬁciency than the positive control RNAiMAX. As 5A2-DOT-10 LNPs were more efﬁcacious than MC3-DOT-10 and C12-200-DOT-10, we performed all subsequent experiments using 5A2-S8. In addition to DOTAP, we also introduced other cationic lipids, including DDAB and EPC, into LNP formulations (Supplementary Fig. 6e–g). The results were similar for all three cationic lipids with different chemical structures (Supplementary Fig. 6h). These results indicate that this strategy is universal for ionizable cationic lipid nanoparticles (DLNPs, LLNPs, SNALPs) and for other cationic lipids that are positively charged at pH 7.4. As our methodology allowed adjustment of the FDA-approved Onpattro® formulation to enable delivery of RNPs, this approach offers new directions for clinically translatable treatment of human diseases.

A key to successful RNP delivery is replacement of the standard acidic buffer with PBS buffer to maintain protein stability. To test if our methodology is compatible with other neutral buffers, we formulated LNPs in PBS, Opti-MEM media, and HEPES. Formulations prepared in citrate buffer (pH 4) were used as a control (Supplementary Fig. 6i). Signiﬁcant and equivalent gene editing was achieved using LNPs prepared in all three neutral buffer conditions, but not in acidic buffer (Fig. 2h and Supplementary Fig. 6j). Sanger sequencing results were consistent with that shown by ﬂow cytometry (Supplementary Fig. 6k). This result further conﬁrmed that neutral buffer was critical for RNP delivery.

Effective multiplexed genome editing was achieved in vivo. To examine in vivo gene editing, we delivered 5A2-DOT-10 encapsulating Cas9/sgTOM complexes to the Td-Tomato mouse (A9 mouse) model (Fig. 3a). The genetically engineered A9 mouse harbors three repeated stop cassettes (SV40 polyA sequences) that prevent expression of the tdTomato ﬂuorescent protein. CRISPR-mediated deletion of two repeat cassettes is sufﬁcient to activate downstream tdTom expression31. This allows facile determination of successfully gene edited cells. We injected 5A2-DOT-10 LNPs loaded with Cas9/sgTOM RNPs into the left leg of mice by intramuscular injection at dose of 1 mg kg−1 sgTOM. Owing to previous use for gene editing via local injection23, RNAiMAX complexed with Cas9/sgTOM RNPs was used for comparison. Higher Td-Tom ﬂuorescence was observed in the muscle treated with 5A2-DOT-10 than in mice treated with RNAiMAX (Fig. 3b). Imaging of tissue sections further conﬁrmed gene editing producing brighter red ﬂuorescence in the 5A2-DOT-10 treatment group (Fig. 3c). Next, we injected 5A2-DOT-10 into the brains of Td-Tom mice (0.15 mg kg−1 of sgTOM). Again, bright red signal was observed near the injection site, conﬁrming editing of mouse brains (Fig. 3d, e). We envision future utility for correction of Central Nervous System diseases.

We next evaluated whether the improved stability and efﬁcacy of 5A2-DOT-10 could mediate successful systemic gene editing in tissues. In parallel to this report, we have explored a variety of additional 5th lipids and formulated a complete methodology for organ-speciﬁc delivery of mRNA10. We found that systematic adjustment of the molar percentage and chemical identity of supplemental molecules precisely modulates tissue biodistribution and release of mRNA in targeted cells. Building on this recent advance, we prepared LNPs with different molar percentages of DOTAP (5–60%) and delivered RNPs to Td-Tom mice IV (1.5 mg kg−1 of sgTOM). Excitingly, Td-Tom ﬂuorescence was observed exclusively in the liver 7 days following injection of 5A2-DOT-5. Increasing the incorporated DOTAP percentage from 5 to 60% resulted in gradual fluorescence
(CRISPR-guided gene editing) from liver to lung. 5A2-DOT-60 enabled mainly lung editing (Fig. 3f and Supplementary Fig. 7). These results indicate that deep tissue editing can be achieved in a tissue-specific manner by adjusting the inner lipid component chemistry and molar ratios. Tissue-specific editing was further confirmed by confocal imaging of tissue sections (Fig. 3g). We next examined editing of an endogenous target, PTEN, by systemically injecting LNPs encapsulating Cas9/sgPTEN RNPs into wild-type C57BL/6 mice. Clear T7EI cleavage bands were only detected in liver for 5A2-DOT-5 treated mice and in the lungs for 5A2-DOT-50 and 5A2-DOT-60 treated mice (Fig. 3h and Supplementary Fig. 20). Next generation deep sequencing (NGS) performed on DNA isolated from mouse livers and lungs further confirmed high gene-editing efficacy (Fig. 3h). In addition, we utilized the Cas-OFFinder prediction webtool to identify the top 10 ranking sgPTEN off-target sites. We then amplified these ten potential off-target sites from 5A2-DOT-50 Cas9/sgPTEN RNPs treated lungs and measured CRISPR-Cas
Fig. 3 Highly efficient multiplexed genome editing was achieved in vivo. a Schematic illustration shows how delivery of Cas9/sgTOM RNP s activates Td-Tom expression in Td-Tomato transgenic mice. 5A2-DOT-X LNPs were injected into Td-Tom mice locally (via intra-muscle or intra-brain injections) and systemically (via IV injection through tail vein). In vivo imaging of Td-Tom mice after intra-muscle (1 mg kg\(^{-1}\) sgTOM) or intra-brain (0.15 mg kg\(^{-1}\) sgTOM) (d) injection of 5A2-DOT-10 Cas9/sgTOM showed bright red fluorescence in the leg muscle or brain tissue (respectively). Successful CRISPR-Cas gene editing was further confirmed by confocal imaging of e muscle and brain tissue sections. Scale bar: 20 μm. 5A2-DOT-10 enabled higher gene editing efficiency than positive control RNAiMAX, which has previously been used for local RNP injections. f In vivo imaging of Td-Tom mice after intravenous (IV) injection of 5A2-DOT-X Cas9/sgTOM LNPs with different molar percentages of DOTAP. Td-Tom fluorescence, as a downstream readout of DNA editing, showed that low DOTAP percentages facilitated liver editing while high DOTAP percentages facilitated lung editing (1.5 mg kg\(^{-1}\) sgTOM, IV). g Successful CRISPR-Cas gene editing was further confirmed by confocal imaging. Scale bar: 20 μm. h The T7E1 cleavage assay was performed on DNA isolated from liver and lung tissues after systemic IV treatment with 5A2-DOT-5, 5A2-DOT-10, 5A2-DOT-50, and 5A2-DOT-60 encapsulating Cas9/sgPTEN. Red arrows indicate cleavage bands generated. Indels (%) was calculated using next generation sequencing (NGS) of DNA isolated from harvested tissues. i 5A2-DOT-50 LNPs containing pooled sgRNAs for six targets (sgTOM, sgP53, sgPTEN, sgEm64, sgALK, and sgRb1) (5A2-DOT-50-Pool) were administered to t-dTom mice IV at total RNA dose of 2 mg kg\(^{-1}\) (0.33 mg kg\(^{-1}\) each sgRNA). Gene editing at the TOM locus was confirmed by in vivo imaging and j editing of the other five loci was confirmed using the T7E1 assay on lung tissues. Indels percentages were measured using Sanger sequencing and TIDE analysis. Red arrows indicate cleavage bands generated. Data of c, e, g, h, and j were repeated three times independently with similar results.

 editing using T7E1 assay. No off-target cutting was observed at any of these off-target sites (Supplementary Figs. 8 and 20).

To evaluate whether it is possible to edit multiple genes in vivo, we encapsulated Cas9 protein and six different sgRNAs into 5A2-DOT-50, sgTOM, sgP53, sgPTEN, sgEm64, sgALK, and sgRb1 were loaded into Cas9 proteins. We then treated Td-Tom mice with 5A2-DOT-50 (Pool) by tail vein injection (0.33 mg kg\(^{-1}\) of each sgRNA). After 1 week, bright Td-Tom fluorescence was detected in the lungs, indicating gene editing of TOM (Fig. 3i). Clear T7E1 cleavage bands were observed at all other five genome loci, demonstrating 5A2-DOT-50 LNPs were able to edit multiple genes in the lungs effectively (Fig. 3i) and Supplementary Fig. 20) at low doses (0.33 mg kg\(^{-1}\) sgRNA). We note that sgRNAs with end modifications of the first and last three nucleotides were used herein to enhance sgRNA stability and reproducibility (Supplementary Fig. 9). Reports have shown that precise modifications to additional nucleotides can increase in vivo gene editing two- to fourfold compared to end-modified sgRNAs, suggesting that the editing efficiencies reported herein could be higher with further sgRNA optimization. Nevertheless, the high potency and tissue specificity of 5A2-DOT-50 allowed for multiplexed editing in the lungs with one injection.

Generation of complex mouse models via intravenous injection. Animal models are traditionally generated by transgenesis or gene engineering in embryonic stem cells, which is time consuming and costly. Direct mutation of tumor- and other disease-related genes in adult mice using CRISPR-Cas provides a feasible approach for rapid generation of models. This has only been accomplished using costly lentiviruses that must be engineered for each target and by hydrodynamic injection into the liver. Since mutation of multiple genes is typically required to generate functional cancer models, the development of an inexpensive and effective non-viral nanoparticle-based approach for multiplexing is highly desirable. Since 5A2-DOT-X LNPs are potent, can simultaneously edit multiple targets, can be administered repeatedly, and provide tissue specificity, they provide a compelling path to generate a wide variety of animal models.

To prove this, we employed 5A2-DOT-5 to knockout three tumor suppressor genes (P53, PTEN, and RB1) selectively in the liver. These genes have been identified in many human cancers, including liver. We treated C57BL/6 mice with weekly IV injections of 2.5 mg kg\(^{-1}\) total sgRNA for 3 weeks and detected the gene editing efficiency in mice livers (Fig. 4a). We observed clear cleavage bands at all three gene loci after treatments of 2, 12, 15, and 20 weeks by T7E1 assay (Fig. 4b and Supplementary Figs. 10, 11, 20). The cleavage bands were much brighter as time progressed, indicating tumor growth. When we sacrificed mice at 15 weeks and 20 weeks, we found visible tumors on the liver, together with several metastatic tumors in the abdominal cavities (Fig. 4b and Supplementary Fig. 12). We also detected the tumor generation by H&E staining and IHC staining targeting tumor proliferation biomarker Ki67 (Fig. 4d and Supplementary Fig. 13) at various time points.

To generate a challenging lung cancer mouse model, we focused on the Eml4-Alk chromosomal rearrangement (Supplementary Fig. 14), which is a complex mutation found in many solid human tumors, especially non-small cell lung cancers. The Eml4-Alk fusion protein generated after rearrangement between Eml4 and Alk promotes cancer development. Exploiting the high potency and lung-targeting specificity of 5A2-DOT-50, we injected once (at dose of 2 mg kg\(^{-1}\) of total sgRNA) or twice (at dose of 1.5 mg kg\(^{-1}\) of total sgRNA, weekly) IV and evaluated the tumor generation process (Fig. 4e). Indel generation was detectable at all examined time points from extracted lung DNA from mice in both groups (Fig. 4f and Supplementary Figs. 15 and 20). More importantly, clear gene rearrangement bands were detected in the lungs of 5A2-DOT-50-treated mice, confirming successfully generated chromosomal rearrangements (Fig. 4g and Supplementary Figs. 15 and 20). The sequencing results after subcloning of these PCR amplicons further confirmed the Eml4-Alk rearrangements (Fig. 4h and Supplementary Fig. 15). We observed several tumor lesions in the lungs after 16 weeks and 24 weeks from H&E staining and Ki67 staining (Fig. 4i and Supplementary Figs. 16 and 17). These results show that a single injection of 5A2-DOT-50 LNPs could successfully generate chromosomal rearrangements and lead to lung tumor generation in adult mice. These LNPs are therefore positioned to greatly accelerate in situ creation of a variety of disease models.

Effective gene editing was achieved in therapeutic models. In addition to demonstrating utility of 5A2-DOT-X LNPs for creation of animal models, we next aimed to examine the potential for therapeutic intervention. To demonstrate disease therapy, we evaluated 5A2-DOT-X in two therapeutic mouse models. First, we utilized the DMD exon 44 deletion mouse model (ΔEx44 DMD mice), which has recently been shown to recapitulate Duchenne muscular dystrophy (DMD). Deletion of exon 44 leads to splicing of exon 43 and 45, disrupting the open-reading frame of dystrophin and introducing a premature termination codon. The reading frame can be restored by using CRISPR-Cas9 gene editing to skip or reframe exon 45, which allows splicing between exons 43 and 46 and restoration of functional dystrophin expression. For this, we injected 5A2-DOT-10 LNPs
After 12, 15, and 20 weeks, mice were sacrificed to analyze tumor generation. Lesions were collected and livers were collected to analyze tumor generation. Scale bar = 100 μm. f To create an in situ lung-specific cancer model, 5A2-DOT-50 LNPs encapsulating Cas9/sgEml4/sgAlk RNPs were injected into adult C57BL/6 mice once (2 mg kg\(^{-1}\)) or twice (1.5 mg kg\(^{-1}\)) weekly (three injections, 2.5 mg kg\(^{-1}\) total sgRNA, IV, n = 4). Among these, the Eml4-Alk rearrangements were also detected in all lungs treated with 5A2-DOT-50 LNPs. g PCR amplions of Eml4-Alk rearrangements were also detected in all treated mice with 5A2-DOT-50 LNPs. h Eml4-Alk rearrangements were further confirmed by sub-cloning and DNA sequencing. i H&E and Ki67 staining further confirmed progressive tumor formation. Higher tumor proliferation biomarker Ki67 expression was detected in lung tumor lesions. Scale bar = 100 μm. Data of b, d, f, g, and i were repeated three times independently with similar results.

The modular strategy described here provided a generalizable approach for tissue-specific gene editing via systemic delivery of RNPs. We discovered that incorporation of a permanently cationic lipid into classic LNP formulations facilitated encapsulation of Cas9 RNPs using neutral buffers, which protected and preserved Cas9 function. By adjusting the molecular components and ratios, we achieved tissue-specific gene editing selectively in the livers and lungs of mice following systemic injection. Excitingly, the lung-targeting 5A2-DOT-50 LNPs showed high editing efficiency. The ability of 5A2-DOT LNPs to target multiple genes and create complex animal models in situ has wide applications for protein function discovery, exploration of biological pathways, and potential long-lasting treatment for chronic and deadly diseases.

**Discussion**

The modular strategy described here provided a generalizable approach for tissue-specific gene editing via systemic delivery of RNPs. We discovered that incorporation of a permanently cationic lipid into classic LNP formulations facilitated encapsulation of Cas9 RNPs using neutral buffers, which protected and preserved Cas9 function. By adjusting the molecular components and ratios, we achieved tissue-specific gene editing selectively in the livers and lungs of mice following systemic injection. Excitingly, the lung-targeting 5A2-DOT-50 LNPs showed high editing efficiency. The ability of 5A2-DOT LNPs to target multiple genes and create complex animal models in situ has wide applications for protein function discovery, exploration of biological pathways, and potential long-lasting treatment for chronic and deadly diseases.
mechanisms, and disease treatment, especially since this can be accomplished with simple IV injections to standard mice of any age. 5A2-DOT LNPs could effectively deliver other proteins (such as ovalbumin) into cell cytoplasm (Supplementary Fig. 19), indicating its significance for other types of protein delivery targeting immunotherapy or protein replacement. The general methodology could also be applied to other delivery systems, including FDA-approved DLin-MC3-DMA SNALPs, further establishing potential translation. The described modular RNP delivery strategy will guide rational design of tissue-specific genomic engineering for a wide variety of preclinical and clinical carriers. We are currently exploring this technology for precise gene correction of various genetic diseases.

Methods

Materials. 5A2-SC8 and C12-200 were synthesized and purified by following published protocols. DLin-MC3-DMA was purchased from MedKoo Biosciences. 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecylammonium (DDAB), 1,2-dimyristoyl-sn-glycero-3-ethphosphocholine (EPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and 1,2-dioleoyl-sn-glycerol-3-phosphocholine (DSPC) were purchased from Avanti Polar Lipids. Cholesterol was purchased from Sigma-Aldrich. 1,2-Dimyoirl-sn-glycerol-methoxy(polyethylene glycol) MW 2000 (DMG-PEG2000) was purchased from NOF America Corporation. The ONE-Glo-Tox Luciferase Reporter assay kit was purchased from Promega Corporation. Pur-A-Lyzer Midi Dialysis Kits (WMCO, 3.5 kDa) were purchased from Sigma-Aldrich. 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI), Hoechst 33342, DLS Ultramicro cuvettes, Lipofectamine RNAiMAX Transfection Reagent, and Lab-Tek chambered cover glass units were purchased from Thermo Fisher Scientific. Cas9 protein and K67 monoclonal antibody was purchased from Thermofisher. Monoclonal anti-dystrophin antibody (D8168) and monoclonal anti-vinculin antibody (Y9131) were purchased from Sigma-Aldrich. GenCrispr NLS Cas9-EGFP Nuclease was purchased from GenScript. Modified sgRNAs (Supplementary Table 1) were purchased from Synthego. All primers (Supplementary Table 2) were synthesized by Integrated DNA Technologies (IDT).

Cas9-sgRNA complex preparation. Separate solutions of Cas9 proteins and sgRNAs in the notated buffers were mixed together at equal volumes. After mixing, the RNPs were allowed to form over 5 min of incubation at room temperature for full Cas9/sgRNA complex self-assembly. The mole ratios of Cas9 protein to sgRNA used were 1/1, 1/3, and 1/5.

Synthesis and purification of 5A2-SC8. First, to a 20 mL vial was equipped with a stir bar was added tetraethylenglycine (5A2, 4.0 g, 1.0 equiv.), and butylated hydroxytoluene (BHT, 838 mg, 0.18 equiv.). The resulting reaction mixture was stirred at 50 °C at 500 r.p.m. for 48 h under N2. The crude product was dissolved in Avanti Polar Lipids. Cholesterol was purchased from Sigma-Aldrich. 1,2-Dimyoirl-sn-glycerol-methoxy(polyethylene glycol) MW 2000 (DMG-PEG2000) was purchased from NOF America Corporation. The ONE-Glo-Tox Luciferase Reporter assay kit was purchased from Promega Corporation. Pur-A-Lyzer Midi Dialysis Kits (WMCO, 3.5 kDa) were purchased from Sigma-Aldrich. 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI), Hoechst 33342, DLS Ultramicro cuvettes, Lipofectamine RNAiMAX Transfection Reagent, and Lab-Tek chambered cover glass units were purchased from Thermo Fisher Scientific. Cas9 protein and K67 monoclonal antibody was purchased from Thermofisher. Monoclonal anti-dystrophin antibody (D8168) and monoclonal anti-vinculin antibody (Y9131) were purchased from Sigma-Aldrich. GenCrispr NLS Cas9-EGFP Nuclease was purchased from GenScript. Modified sgRNAs (Supplementary Table 1) were purchased from Synthego. All primers (Supplementary Table 2) were synthesized by Integrated DNA Technologies (IDT).

Synthesis and purification of 5A2-SC8. First, to a 20 mL vial was equipped with a stir bar was added tetraethylenglycine (5A2, 4.0 g, 1.0 equiv.), 2-(acyryloyoxy)ethyl methacrylate (AEMA, 20.4 g, 5.25 equiv.), and butylated hydroxytoluene (BHT, 838 mg, 0.18 equiv.). The resulting reaction mixture was stirred at 50 °C at 500 r.p.m. for 24 h under N2. The crude product was purified by flash column chromatography (silica, 30 to 50% acetone/hexanes with 3% triethylamine) to achieve the 5A2-G1 (5.2 g, 19%). Ref = 0.15 (30% acetone/hexanes with 3% triethylamine, silica). Second, to a 20 mL vial was equipped with a stir bar was added 5A2-G1 (3.9 g, 1.0 equiv.), dimethylphenylphosphine (DMMP, 193 mL, 0.45 equiv.), and 1-octanethiol (SC8, 4.71 mL, 6.15 equiv.). The resulting reaction mixture was stirred at 55 °C at 500 r.p.m. for 48 h under N2. The crude product was dissolved in a minimal amount of CH2Cl2 and purified by flash column chromatography (neutral Al2O3, 20 to 100% of ethyl acetate/hexanes) to yield 5A2-SC8 (4.2 g, 64%). Ref = 0.2 (70% ethyl acetate/hexanes, neutral Al2O3). HRMS Calc. for C110H203N5O24S6:2170.31, found: 2170.29.

Synthesis and purification of C12-200. The synthetic protocol was based on a previous report63. First, N1-[2-(4-aminoethyl)pyraperazin-1-yl]acetoxime (1.0 g) was hydrogenated with H2 (g) at 60 psi along with Raney-Nickel 2400 (5 mL slurry, 2.5 g), 25% NH4OH (28 mL), and ethanol at r.t. for 23 h. Following workup, 0.98 g N1-[2-(4-aminoethyl)
piperazine-1-yl)ethyl)ethane-1,2-diamine was obtained (85.6% yield). Next, N1-(2-(4-(2-aminoethyl)piperazine-1-yl)ethyl)ethane-1,2-diamine was reacted neat with 10% fetal bovine serum, and treated with 50 mM (4-(2-aminoethyl)piperazin-1-yl)ethyl)ethane-1,2-diamine was reacted neat with 10% fetal bovine serum, and treated with 50 NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17029-3 | www.nature.com/naturecommunications  (4-(2-aminoethyl)piperazin-1-yl)ethyl)ethane-1,2-diamine was reacted neat with 10% fetal bovine serum, and treated with 50 NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17029-3 | www.nature.com/naturecommunications

Optimized nanoparticle formulations and characterization. Ionomizable cationic lipids (5A2 SCR, for Dlino-MC3-DMA) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (DOPE or DSPC), cholesterol, DMG-PEG, and permanently cationic lipids (DOTAP, DDB, or EPC) were dissolved in ethanol at given molar ratios. Cas9/sgRNA complexes were dissolved in 1× PBS buffer. The Cas9/sgRNA RNP complexes solution in PBS buffer was pipette mixed rapidly into the lipids solution in ethanol at a volume ratio of 3:1 (Cas9/sgRNA RNP:lipids, v/v), such that the weight ratio of total lipids to sgRNA was 40:1 (wt/wt), then incubated for 15 min at room temperature. Afterwards, the fresh formulations were directly characterized and used for in vitro assays. For animal experiments, the formulations were dialyzed (Pur-A-Lyzer Midi Dialysis Kits, WMCO 3.5 kDa) against 1× PBS for 1 h to remove ethanol before topical applications (intra-muscle or intra-brain injection) or systemic injection (intravenous injection). The size distribution and zeta potential of nanoformulations were measured using Zetasizer (version 7.13, Malvern Panalytical; He-Ne Laser, λ = 632 nm; detection angle = 173°).

RNAiMAX formulations. For preparation of RNAiMAX complexing RNPs, the Cas9/sgRNA complex was prepared in Opti-MEM and mixed gently with lipofectamine RNAiMAX reagent gently mixed in Opti-MEM (at dose of 1 μl RNAiMAX per μg sgRNA). The mixture solution was incubated at room temperature for 30 min to complete the complexation.

Standard LNP formulations. For preparation of C12-200 and MC3 LNPs encapsulating RNPs, Cas9/sgRNA RNP complexes solution in citrate buffer (pH 4.0) was pipette mixed rapidly into the lipids solution in ethanol at a volume ratio of 3:1 (Cas9/sgRNA RNP:lipids, v/v), such that the weight ratio of total lipids to sgRNA was 40:1 (wt/wt), then incubated for 15 min at room temperature. The molar ratio of C12-200/DOPE/Chol/DMG-PEG was 35/16/46/5.2/5 for C12-200 LNPs; the molar ratio of DLin-MC3-DMA/DSPC/Chol/DMG-PEG was 50/10/38.5/1.5 for MC3 LNPs.

Cellular uptake and uptake mechanism. To examine cellular uptake, HeLa-Luc cells were seeded into Lab-Tek Chambered Coverglass (eight wells) at a density of 2 × 10^5 cells per well, and incubated at 37 °C overnight. Then, the old media was replaced with 150 μl of fresh Dulbecco’s modified Eagle Medium (DMEM) containing 10% fetal bovine serum, and treated with 50 μl of 5A2-DOT-10 encapsulating Cas9-EGFP/sgLuc RNPs (9 μM of sgRNA per well). At 1, 3, 6, and 24 h after treatment, cells were washed three times with PBS and stained with Hoechst (0.1 mg ml−1) for 15 min at 37 °C, then imaged by confocal microscopy (Zeiss LSM 700) and data were analyzed using ZEN 2010 software version 6.0.2. (Carl Zeiss MicroImaging GmbH). To examine the uptake mechanism, assays of specific inhibition on endocytosis pathway were performed using HeLa-Luc cells. 5A2-DOT-10 LNPs were used as a control. HeLa-Luc cells were seeded at a density of 5 × 10^5 cells per well in 12-well plates and incubated in DMEM complete medium for 24 h. The cells were then washed with PBS and followed by pre-incubating at 37 °C for 1 h with one of the following endocytosis inhibitors dissolved in Opti-MEM: 20 μM chlorpromazine (CMZ, an inhibitor of clathrin-mediated endocytosis), 2 mM Amlodipine (AMI, an inhibitor of macrocytophagy), 200 μM Genistein (GEN, an inhibitor of caveolae-mediated endocytosis), 5 mM methyl-β-cyclodextrin (MβCD), an inhibitor of lipid raft-mediated endocytosis).

Stability of 5A2-DOT-10 Cas9-sgGFP. To measure stability, we prepared 5A2-DOT-10 LNPs encapsulating Cas9/sgGFP RNPs complex and stored them at 4 °C for 2 months. The size and PDI of these nanoparticles were tested after storing for different times and their gene editing efficiency were also evaluated in HeLa-GFP cells by adding nanoparticles (24 nM sgRNA dose) and quantifying gene editing after 3 days. For each time point, an aliquot of stored 5A2-DOT-10 LNPs encapsulating Cas9/sgGFP RNPs was taken and analyzed (size, PDI, efficacy).

Animal experiments. All animal experiments were approved by the Institution Animal Care and Use Committee of The University of Texas Southwestern Medical Center and were consistent with local, state, and federal regulations as applicable. Mice were housed in a barrier facility with a 12-h light/dark cycle and maintained on standard chow (2916 Teklad Global). C57BL/6 mice were obtained from the Jackson Laboratory (007909) and bred to maintain homozygous expression of the Cre reporter allele that has a loxp-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent tdTomato protein. Following Cas9/sgRNA lentiviral gene editing, Ai9 mice will express fluorescent tdTomato protein. All animal experiments were performed using an IVIS Lumina system (Perkin Elmer). Afterwards, the muscle tissues were embedded in optimal cutting temperature (OCT) compound and cut into 10 μm slices. The sections were fixed with 4% Paraformaldehyde (Thermo Fisher Scientific) for 20 min, washed three times using PBS buffer. Afterwards, one drop of ProLong Gold Mountant with DAPI (Thermo Fisher Scientific) was applied onto each slide. A coverslip was placed, and the slides were imaged by confocal microscopy (Zeiss LSM 700) and data were analyzed using ZEN 2010 software version 6.0.2. (Carl Zeiss MicroImaging GmbH). For in vivo editing in muscle, Td-Tomato mice were injected with Cas9/sgTOM RNPs and examined with IVIS Lumina system (version 4.4.0.0, Caliper Life Sciences). Frozen sections of brains were prepared as the protocol mentioned above and imaged by confocal microscopy. For gene editing by iv injection, mice were treated with 5A2-DOT-X LNPs encapsulating Cas9/sgTOM RNPs complex at dose of 0.15 mg kg−1 of sgTOM in the left leg by intra-muscle injection. RNAiMAX encapsulating Cas9/sgTOM RNPs complex was used as positive control. After treatment for 7 days, the muscle tissues of all treatment groups were collected and imaged using an IVIS Lumina system (Perkin Elmer). Afterwards, the muscle tissues were embedded in optimal cutting temperature (OCT) compound and cut into 10 μm slices. The sections were fixed with 4% Paraformaldehyde (Thermo Fisher Scientific) for 20 min, washed three times using PBS buffer. Afterwards, one drop of ProLong Gold Mountant with DAPI (Thermo Fisher Scientific) was applied onto each slide. A coverslip was placed, and the slides were imaged by confocal microscopy (Zeiss LSM 700) and data were analyzed using ZEN 2010 software version 6.0.2. (Carl Zeiss MicroImaging GmbH). For in vivo editing in brain, Td-Tomato mice were injected with Cas9/sgTOM RNPs and examined with IVIS Lumina system (version 4.4.0.0, Caliper Life Sciences). Frozen sections of brains were prepared as the protocol mentioned above and imaged by confocal microscopy. For gene editing by iv injection, mice were treated with 5A2-DOT-X LNPs encapsulating Cas9/sgTOM RNPs complex at dose of 0.15 mg kg−1 of sgTOM in the left leg by intra-muscle injection. After treatment for 6 days, the brains were excised and imaged using IVIS Lumina system (version 4.4.0.0, Caliper Life Sciences). Frozen sections of brains were prepared as the protocol mentioned above and imaged by confocal microscopy.
male A/Jx4 DMD mice (at dose of 1 mg kg\(^{-1}\) of sgDMD) three times (once per week). Three weeks after the last injection, the TA muscles were removed for western blot (dilution of anti-dystrophin antibody at 1:1000 and dilution of anti-veclin antibody at 1:5000) and immunofluorescence analyses (n = 3 biologically independent animals). SA2-DOT-10 nanoparticle only treatment group was used as negative control. Quantification of restored dystrophin expression was analyzed using Image J (1.50b Java 1.8.0_60) (64-bit), National Institutes of Health, USA) based on western blot result.

In vivo PCSK9 gene editing in C57BL/6 mice. SA2-DOT-5 encapsulating sgPCSK9 was injected into C57BL/6 mice by tail vein injection (at dose of 2.5 mg kg\(^{-1}\) of sgPCSK9) three times (once per week). One week after the last injection, mouse serum was collected to detect serum PCSK9 level using a PCSK9 Elisa Kit (ab1215538, Abcam). The mice were then sacrificed, and liver tissues were collected to detect gene editing at the PCSK9 gene locus by T7EI assay, Sanger sequencing and western blot. PBS treatment group and SA2-DOT-5 nanoparticle only treatment group were used as negative controls (n = 3).

Next generation sequencing. The PCR amplicons at PTFEN locus were amplified using genome DNA extracted from tissues treated with different SA2-DOT-X nanoflomulations. Then these samples were mailed to GENEWIZ Company to detect gene editing efficiencies using next-generation deep sequencing (NGS).

PCR for Em4-Alk rearrangements. The in vivo Em4-Alk rearrangements were tested by nested PCR.\(^{45}\) For the first round PCR, 40 ng of genomic DNA was used as template with PCR program of 95 °C for 5 min; (95 °C for 30 s; 64 °C for 30 s; 30 s; 72 °C for 30 s) for 18 cycles; 72 °C for 7 min and then keep at 4 °C. For the second round PCR, 1 μl of the first round PCR product (100 dilutions) was used for PCR reactions (95 °C for 5 min; (95 °C for 30 s; 68 °C for 30 s; 72 °C for 30 s) for 30 cycles; 72 °C for 7 min and then keep at 4 °C. Primers used in the PCR reactions are listed in Supplementary Table 2. PCR amplified targeting gene GAPDH was used as internal control.

Measurement of off-target effects. Top-10 potential off-target sites were predicted using Cas-OFFinder webtool and these sites were amplified by PCR, then analyzed using T7EI assay. Relative primer information is listed in Supplementary Table 2.

H&E staining and immunohistochemistry (IHC). Briefly, 10% formalin solution fixed tissues were embedded in paraffin, sectioned and H&E stained by the Molecular Pathology Core at UTSW. The 4 μm sections were performed in the standard fashion and detected with Elite ABC Kit and DAB Substrate (Vector Laboratories) for IHC. These slides were scanned using NANOZOOMER (NDP. Laboratories) and analyzed using NDP.view 2 software (version 2.7.25, Hamamatsu).

Display items. The images of mice (Figs. 1a, 3a, 4a, 5a, d), syringes (Figs. 1a, 4a, e, 5a, d), and organs (Figs. 1a, 4a, e) were created with BioRender.com.

Statistical analyses. Statistical analyses were performed by one-way ANOVA followed by Dunnett’s multiple comparison test, using GraphPad Prism software, version 7.04 (GraphPad Software, USA). A P-value < 0.05 was considered statistically significant.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. The source data for the Figures along with the Supplementary Figures presented in this paper are available in the Source Data file. Sequencing data is available from the Sequence Read Archive under accession code PRINAA634601. All other relevant data that support all findings within this paper are available from the corresponding author upon request. Source data are provided with this paper.

Received: 20 April 2020; Accepted: 27 May 2020; Published online: 26 June 2020

References
1. Wang, H. X. et al. CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem. Rev. 117, 9874–9906 (2017).
2. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
3. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
4. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
5. Xue, W. et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380–384 (2014).
6. Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).
7. Long, C. Z. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400–403 (2016).
8. Maddalo, D. et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516, 423–427 (2014).
9. Schwank, G. et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13, 653–658 (2013).
10. Liu, C., Zhang, L., Liu, H. & Cheng, K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J. Control Release 266, 17–26 (2017).
11. Duncan, D. C., Lee, Y. W., Nagarai, H., Scalfetti, F. & Rotello, V. M. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges. Expert Opin. Drug Deliv. 15, 905–913 (2018).
12. Miller, J. B. et al. Non-viral CRISPR/Cas9 gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew. Chem. Int. Ed. 56, 1059–1063 (2017).
13. Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).
14. Zhu, H. B. et al. Spatial control of in vivo CRISPR/Cas9 genome editing via nanomagnets. Nat. Biomed. Eng. 3, 126–126 (2019).
15. Ramakrishna, S. et al. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24, 1020–1027 (2014).
16. Li, X. Q. et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 206, 44–53 (2015).
17. Lattanzi, A. et al. Optimization of CRISPR/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genetic rearrangements. Mol. Ther. 27, 137–150 (2019).
18. Mout, R., Ray, M., Lee, Y. W., Scalfetti, F. & Rotello, V. M. In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges. Bioconjugate Chem. 28, 880–884 (2017).
19. Li, L., Hu, S. & Chen, X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials 171, 207–218 (2018).
20. Xu, C. F. et al. Rational designs of in vivo CRISPR-Cas delivery systems. Adv. Drug Delivey. Rev. https://doi.org/10.1016/j.addr.2019.1011.0059 (2019).
21. Wang, L., Zheng, W., Liu, S., Li, B. & Jiang, X. Delivery of CRISPR/Cas9 by novel strategies for gene therapy. ChemBiochem 20, 634–643 (2019).
22. Sun, W. J. et al. Self-assembled DNA nanoclewes for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. 54, 12029–12033 (2015).
23. Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80 (2015).
24. Wang, M. et al. Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc. Natl Acad. Sci. USA 113, 2868–2873 (2016).
25. Gao, X. et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature 553, 217–221 (2018).
26. Lee, K. et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901 (2017).
27. Mout, R. et al. Direct cytosolic delivery of CRISPR/Cas9 ribonucleoprotein for efficient gene editing. ACS Nano 11, 2452–2458 (2017).
28. Wang, P. et al. Genome editing for cancer therapy: delivery of Cas9 protein/sgRNA plasmid via a gold nanocluster/lipid core-shell nanocarrier. Adv. Sci. 4, 1700175 (2017).
29. Alsaiari, S. K. et al. Endosomal escape and delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol. 35, 431–434 (2017).
32. Doudna, J. A. & Charpentier, E. Genome editing: the new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258896 (2014).
33. Sander, J. D. & Joung, J. K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32, 347–355 (2014).
34. Wood, H. F. FDA approves Patisiran to treat hereditary transthyretin amyloidosis. Nat. Rev. Neurol. 14, 570 (2018).
35. Zhang, S. et al. Knockdown of anillin actin binding protein blocks cytokinesis in hepatocytes and reduces liver tumor development in mice without affecting hepatocellular regeneration. Gastroenterology 154, 1421–1434 (2018).
36. Zhou, K. et al. Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model. Proc. Natl. Acad. Sci. USA 113, 520–525 (2016).
37. Zhang, S. et al. Knockdown of anillin actin binding protein blocks cytokinesis in hepatocytes and reduces liver tumor development in mice without affecting hepatocellular regeneration. Gastroenterology 154, 1421–1434 (2018).
38. Cheng, Q. et al. Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv. Mater. 30, e1805308 (2018).
39. Cheng, Q. et al. Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Adv. Mater. 30, e1805308 (2018).
40. Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas9 genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).
41. Blasco, R. B. et al. Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 9, 1219–1227 (2014).
42. Min, Y. J. et al. CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 5, eaav4324 (2019).
43. German, D. M., Mitalipov, S., Mishra, A. & Kaul, S. Therapeutic genome editing in cardiovascular diseases. JACC Basic Transl. Sci. 4, 122–131 (2019).
44. Hess, C. N., Low Wang, C. C. & Hiatt, W. R. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu. Rev. Med. 69, 133–145 (2018).
45. Love, K. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010).
46. Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529–8533 (2012).

Acknowledgements
D.J.S. acknowledges financial support from the Cystic Fibrosis Foundation (CFF) (SIEGWA18XX0), National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) (R01 EB025192-01A1), American Cancer Society (ACS) (RSG-17-012-01), and the Robert A. Welch Foundation (I-1855). T.W. acknowledges financial support from the Cancer Prevention and Research Institute of Texas (CPRIT) Training Grant (RP160157). E.N.O. acknowledges support from NIH (HL130253 and AR067294), Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (USA HD 08351), the Robert A. Welch Foundation (grant 1-0025), and a sponsored research agreement with Vertex Pharmaceuticals. We acknowledge the UTSW Tissue Resource, supported in part by the National Cancer Institute (5P30CA142543), and the Moody Foundation Flow Cytometry Facility. We thank Dr. Yonglong Wei and Prof. Hao Zhu for assistance with tissue processing and analysis. We thank Lukas Farbiak for preparing schemes and images for this manuscript.

Author contributions
T.W., Q.C., and D.J.S. designed the research and wrote the manuscript. T.W., Q.C., and Y.-L.M. performed the experiments. E.N.O. and D.J.S. supervised the research.

Competing interests
D.J.S., Q.C., T.W., and the Reagents of the University of Texas System have filed patent applications (PCT/US19/49552 and PCT/US19/49565) on the compositions and methods for organ-specific delivery of nucleic acids. D.J.S. is a co-founder of, and consultant to, ReCode Therapeutics, which has licensed intellectual property from UT Southwestern. Y.-L.M. is currently an employee of Vertex Pharmaceuticals. E.N.O. is a consultant for Vertex Pharmaceuticals.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-020-17029-3.

Correspondence and requests for materials should be addressed to D.J.S.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020